Skip to main content

Table 4 Changes in CRP and ESR with treatment

From: Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure

Time Change in CRP (n = 37) Change in ESR (n = 20)
  oMTX rMTX oMTX rMTX
3 months -1.5 (-28.0 and +24.2) -7.0 (-49.0 and +52.2) -7.0 (-32.7 and +24.5) -25.6 (-33.0 and +23.1)
6 months -13.9 (-59.6 and +16.2) -11.5 (-49.4 and +22.2) -20.6 (-50.9 and +19.9) -12.1 (-38.2 and +52.5)
9 months -20.9 (-60.1 and +19.0) -14.8 (-50.4 and +38.4) -15.3 (-50.6 and +22.2) -24.2 (-55.3 and +37.6)
12 months -23.6 (-51.6 and +6.8) -26.8 (-68.8 and +0.0) -20.2 (-51.0 and +41.1) -36.1 (-61.5 and +16.1)
AUC -14.0 (-41.2 and +16.8)* -10.3 (-53.0 and +37.9)* -6.1 (-27.6 and +20.4)** -17.7 (-45.9 and +25.1)**
  1. Shown are the relative improvements in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) at 3, 6, 9, and 12 months after treatment initiation. Values are expressed as median (1st and 3rd quartile) of % change. *P = 0.80, by Wilcoxon test; **P = 0.43, by Wilcoxon test. oMTX, original methotrexate course; rMTX, re-employed methotrexate course.